#USA #San Diego #Phanes Therapeutics #Colorectal Cancer #Spevatamig

Phanes Therapeutics Advances Cancer Treatment Research

Phanes Therapeutics, Inc., a clinical-stage biotechnology company specializing in immuno-oncology, recently announced a significant milestone in its groundbreaking research. The company has dosed the first patient in a clinical trial evaluating spevatamig as a treatment option for colorectal cancer (CRC). This development heralds a new era in cancer therapies focused on utilizing innovative drug discovery and development techniques.

What is Spevatamig?

Spevatamig is a first-in-class bispecific antibody designed to target claudin 18.2 and CD47, two proteins that play critical roles in cancer progression. By focusing on these specific targets, spevatamig aims to enhance the body’s immune response against tumors. Its implications are particularly promising, as it is the first innate immunity enhancer (I2E) identified for solid tumors, which sets it apart from other therapies currently in development.

The drug has previously received several important designations from the Food and Drug Administration (FDA), including orphan drug designation for pancreatic cancer in 2022 and Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024. Most recently, it received Fast Track designation for treating advanced and metastatic biliary tract carcinoma.

Phanes Therapeutics has embarked on a clinical collaboration with Merck (known as MSD outside North America) to explore the effectiveness of spevatamig when used in conjunction with pembrolizumab, a checkpoint inhibitor that has shown effectiveness in various cancers. This collaboration underscores the potential for spevatamig to be combined with other anti-cancer therapies, enhancing its clinical utility and effectiveness.

The TWINPEAK Study

The TWINPEAK study operates as a multi-center Phase I/II clinical trial, specifically assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced gastrointestinal cancers. These include gastric, gastroesophageal junction, pancreatic ductal, CRC, and biliary tract adenocarcinomas. The Phase I trials (CTR20241655) and Phase II trials (CTR20252758) are also underway in China, actively recruiting patients.

As studies advance, Phanes aims to establish comprehensive data regarding spevatamig’s performance across various gastrointestinal cancers, potentially reshaping treatment paradigms and improving outcomes for patients battling these challenging diseases.

Company Profile: Phanes Therapeutics

Founded with a commitment to innovative drug discovery, Phanes Therapeutics is making remarkable strides in the immuno-oncology sector. With a robust four-stage pipeline designed to tackle significant unmet medical needs in oncology, the company is currently engaged in three Phase 2 clinical trials involving spevatamig, peluntamig, and mavrostobart. Both spevatamig and peluntamig have achieved orphan drug and Fast Track designations, representing recognition from the FDA regarding their therapeutic potential.

Phanes leverages proprietary technology platforms, including PACbody, SPECpair, and ATACCbody, to develop novel biologics that aim to address pressing clinical challenges in cancer treatment.

As they continue to expand their research capabilities and pipeline, Phanes Therapeutics remains dedicated to creating impactful therapies that could revolutionize the way cancers are treated. For further information regarding their initiatives and research, visit Phanes Therapeutics.

Conclusion

The dosing of the first patient in the TWINPEAK study represents not only a significant milestone for Phanes Therapeutics but also for the field of cancer treatment as a whole. As this clinical trial continues to unfold, the potential of spevatamig could redefine therapeutic strategies for colorectal cancer and other advanced gastrointestinal malignancies.